Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Torrent Pharma shares...

    Torrent Pharma shares slump 3pc on USFDA warning letter for Gujarat facility

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-11T09:15:47+05:30  |  Updated On 16 Aug 2021 11:49 AM IST

    Torrent Pharma does not believe that the warning letter will have an impact on the disruption of supplies or the existing revenues from operations of this facility, the company added.


    New Delhi: Shares of Torrent Pharmaceuticals slumped nearly 3 per cent on Thursday after the company said it has received a warning letter from the US health regulator for its Indrad facility in Gujarat. The stock of the drug firm was down 2.61 per cent at Rs 1,622.60 on the BSE.


    The scrip was trading 2.59 per cent lower at Rs 1,623 on the NSE.


    Torrent Pharma on Wednesday said it has received a warning letter from the US health regulator for its Indrad facility in Gujarat.


    This action by the United States Food and Drug Administration (USFDA) follows earlier intimation received from the regulator in August 2019, wherein the agency had classified its inspection as "Official Action Indicated" (OAI), Torrent Pharma said in a regulatory filing on Wednesday.


    Read Also: Torrent Pharma Indrad facility gets USFDA warning letter


    The company does not believe that the warning letter will have an impact on the disruption of supplies or the existing revenues from operations of this facility, it added.


    "We will be engaging with the agency and are fully committed to resolving this issue at the earliest," Torrent Pharma said.


    The company is also committed to maintaining the highest standards of compliances and quality manufacturing across all its facilities, it added.


    Read Also: Torrent Pharma expands recall of Losartan tablets in US over carcinogen impurity

    BSENSEoaiOfficial Action Indicatedpharmapharma companypharma newspharma news indiaTorrentTorrent PharmaTorrent Pharma Indrad planttorrent sharesUS health regulatorUSFDAUSFDA warning
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok